Pediatric Optic Pathway Gliomas: A Report From Northern Greece

被引:1
作者
Panagopoulou, Paraskevi [1 ]
Athanasiadis, Dimitrios [2 ]
Anastasiou, Athanassia [3 ]
Zafeiriou, Dimitrios [4 ]
Papakonstantinou, Evgenia [2 ]
机构
[1] Aristotle Univ Thessaloniki, Dept Pediat 4, Thessaloniki, Greece
[2] Ippokration Hosp, Dept Pediat Oncol, Thessaloniki, Greece
[3] Ippokration Hosp, Dept Pediat Radiol, Thessaloniki, Greece
[4] Aristotle Univ Thessaloniki, Ippokration Hosp, Dept Pediat 1, Thessaloniki, Greece
关键词
optic pathway glioma; low-grade glioma; brain tumors; chemotherapy; neurofibromatosis type 1; LOW-GRADE GLIOMA; SPONTANEOUS REGRESSION; BRAIN-TUMOR; CHILDREN; OUTCOMES; CLASSIFICATION; ASTROCYTOMAS; RADIOTHERAPY; EXPERIENCE; RADIATION;
D O I
10.1097/MPH.0000000000002753
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Optic pathway gliomas (OPGs) are the most common pediatric optic nerve tumors. Their behavior ranges between rapid growth, stability, or spontaneous regression. tau hey are characterized by low mortality albeit with significant morbidity. We present the characteristics, management, and outcome of 23 OPG patients (16 females, median age: 4.8 y) managed in a Pediatric Oncology Department in Northern Greece over a 25-year period. Overall, 57% had a background of neurofibromatosis type 1. Diagnosis was based on imaging (10 patients) or biopsy (13 patients). Presenting symptoms were mostly visual impairment/squint (52%). Proptosis/exophthalmos, raised intracranial pressure, and headache were also noted. In 2 occasions, it was detected with surveillance magnetic resonance imaging in the context of neurofibromatosis type 1. Eight patients had unilateral and 2 bilateral optic nerve tumors (Modified Dodge Classification, stage 1a/1b), 3 had chiasmatic (stage 2a/b), and 10 had multiple tumors (stage 3/4). Predominant histology was pilocytic astrocytoma (77%). Management included: observation (4), chemotherapy only (9), surgery only (3), or various combinations (7). Chemotherapy regimens included vincristine and carboplatin, vinblastine, or bevacizumab with irinotecan. Most patients demonstrated a slow disease course with complete response/partial response to chemotherapy and/or surgery, whereas 39% presented >= 1 recurrences. After a median follow-up of 8.5 years (range to 19 y), 20 patients (87%) are still alive with stable disease, in partial/complete remission, or on treatment.
引用
收藏
页码:445 / 451
页数:7
相关论文
共 49 条
  • [41] Pediatric low-grade glioma in the era of molecular diagnostics
    Ryall, Scott
    Tabori, Uri
    Hawkins, Cynthia
    [J]. ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2020, 8 (01)
  • [42] Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management
    Sturm, Dominik
    Pfister, Stefan M.
    Jones, David T. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (21) : 2370 - +
  • [43] The clinical presentation of children with tumours affecting the anterior visual pathways
    Suharwardy, J
    Elston, J
    [J]. EYE, 1997, 11 (6) : 838 - 844
  • [44] Radiological classification of optic pathway gliomas: experience of a modified functional classification system
    Taylor, T.
    Jaspan, T.
    Milano, G.
    Gregson, R.
    Parker, T.
    Ritzmann, T.
    Benson, C.
    Walker, D.
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2008, 81 (970) : 761 - 766
  • [45] Treatment Options for Optic Pathway Gliomas
    Thomas, Reena P.
    Gibbs, Iris C.
    Xu, Linda Wei
    Recht, Lawrence
    [J]. CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2015, 17 (02)
  • [46] A new era for optic pathway glioma: A developmental brain tumor with life-long health consequences
    Walker, David A.
    Aquilina, Kristian
    Spoudeas, Helen
    Pilotto, Chiara
    Gan, Hoong-Wei
    Meijer, Lisethe
    [J]. FRONTIERS IN PEDIATRICS, 2023, 11
  • [47] Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1
    Wan, Michael J.
    Ullrich, Nicole J.
    Manley, Peter E.
    Kieran, Mark W.
    Goumnerova, Liliana C.
    Heidary, Gena
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2016, 129 (01) : 173 - 178
  • [48] Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review
    Yamasaki, Fumiyuki
    Takano, Motoki
    Yonezawa, Ushio
    Taguchi, Akira
    Kolakshyapati, Manish
    Okumichi, Hideaki
    Kiuchi, Yoshiaki
    Kurisu, Kaoru
    [J]. CHILDS NERVOUS SYSTEM, 2020, 36 (03) : 635 - 639
  • [49] Zizka J, 2001, EUR RADIOL, V11, P2638